uniQure N.V. (NASDAQ:QURE) Stock Has Average Price Target of $53.25

Shares of uniQure N.V. (NASDAQ:QURE) have received an average recommendation of “Moderate Buy” from the seventeen analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, twelve have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $53.25.

A number of research firms have weighed in on QURE. UBS Group reaffirmed a “buy” rating and set a $48.00 target price (up from $27.00) on shares of uniQure in a report on Thursday, October 15th. Barclays cut uniQure from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $60.00 to $28.00 in a research report on Monday, October 5th. Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a report on Saturday, September 5th. Royal Bank Of Canada cut their price objective on shares of uniQure from $65.00 to $48.00 and set an “outperform” rating for the company in a research report on Friday, October 2nd. Finally, William Blair raised shares of uniQure to a “strong-buy” rating in a research note on Wednesday, September 23rd.

uniQure Stock Performance

NASDAQ:QURE opened at $22.43 on Wednesday. uniQure has a 1 year low of $8.73 and a 1 year high of $71.50. The stock’s fifty day moving average price is $36.88 and its two-hundred day moving average price is $34.02. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The company had revenue of $5.84 million during the quarter, compared to analysts’ expectations of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same quarter last year, the firm posted ($0.69) earnings per share. On average, research analysts anticipate that uniQure will post -3.82 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Orbimed Advisors LLC increased its holdings in shares of uniQure by 189.7% in the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after purchasing an additional 1,398,749 shares during the period. Two Seas Capital LP purchased a new stake in shares of uniQure in the third quarter worth $31,988,000. Siren L.L.C. bought a new stake in uniQure during the first quarter valued at $16,350,000. SG Americas Securities LLC boosted its stake in uniQure by 1,107.3% during the first quarter. SG Americas Securities LLC now owns 776,604 shares of the biotechnology company’s stock valued at $12,697,000 after buying an additional 712,278 shares during the period. Finally, Maverick Capital Ltd. grew its position in uniQure by 5.4% during the first quarter. Maverick Capital Ltd. now owns 697,640 shares of the biotechnology company’s stock worth $11,406,000 after buying an additional 35,820 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.